Niagen Bioscience, Inc.
NAGE · Healthcare · $256M mkt cap · FY2025 filings · · not refreshed in 36 days · Narrow moat ·
On the watchlist
The five investor questions
2021–2025 (latest 5 aligned FYs; v3 window cap 5): revenue $67.4M to $129M, increasing; diluted EPS -0.40 to 0.20, increasing.
Median gross margin 59.5% over 10y, stable.
Median ROIC -175.8%, above the 12% hurdle in 22% of years.
Net cash position — no leverage risk.
Owner earnings changed trend unclear over up to the ten most recent annual observations.
Price vs. value if growth stopped today
A cautious baseline, not a price target: what the shares may support if normalized owner earnings simply hold steady.
- Not reported
- Unavailable — insufficient owner-earnings data
- Unavailable — insufficient growth-model data
- $3.21
- No price data
This zero-growth estimate assumes trailing owner earnings persist — unreliable for declining businesses. The recent FY revenue series does not trigger the three-consecutive-declines flag.
Among the current top-score group, the median current price is 239% above the zero-growth estimate across 48 of the current top 50 companies by Moat Score with both values.
Score records captured Jul 26, 2026.
Exactly which 50 companies?
FTNT, META, MEDP, IBEX, MSFT, GOOGL, LULU, ANF, IDXX, TXRH, FHI, QLYS, FFIV, ADBE, LLY, MANH, VEEV, GRMN, SSD, MNST, DOCS, MCO, CPRT, NTAP, LRCX, NVDA, CORT, SFM, MPTI, ULTA, SN, RMD, ROL, PAYC, IRMD, INTU, DECK, MORN, LGCY, DAL, GWW, ISRG, MPWR, CTAS, LOPE, MRK, CMG, FAST, BKNG, ORLY
Missing a usable price or zero-growth estimate: ANF, BKNG.
Model details under moat-index@3.0.0: zero-growth multiple 11.1×, capped-growth comparison at no more than 18×; 9% discount rate; high-end growth 0% (capped at 4%) using min(5y revenue CAGR, 5y diluted-EPS CAGR), clamped to 0%–4%; maintenance capex uses min(capex, D&A); abstain when D&A is unavailable. This is a disclosed model range, not intrinsic value as fact.
17 years of fundamentals
The business, in plain English
Niagen Bioscience, Inc. booked $129M of revenue in FY2025 in the Healthcare sector and kept 64.3% of it as gross profit — a high-margin business by that measure. After every other cost, 13.4% of each revenue dollar reached the bottom line.
Across the filed record, revenue grew from $7.6M (FY2010) to $129M (FY2025) — about 20.8% a year compounded over 15 years.
It earned 132.4% on invested capital in the latest filed year, FY2025. Across the full 15-year measurable filed record, median ROIC was −66.7%. Over the v3 recent window (9 measurable filed years), median ROIC was −175.8%. The Returns on Capital filter above scores it 8/100.
NAGE's latest filed year, FY2025, doesn't disclose total debt in a form the methodology can use, so current leverage is treated as unmeasured — never assumed to be zero.
Put together: Balance-Sheet Safety is the strongest of the five filters (100/100) and Returns on Capital the weakest (8/100), which is how NAGE lands at 62/100 — a Narrow moat.
This breakdown is generated from the filed numbers and sub-scores above — no outside narrative, no estimates. Where a filing doesn’t disclose an input, the sentence that would need it is omitted instead of guessed.
Gaps in a line mean that item isn’t in NAGE’s filings for that year. The series is never interpolated or estimated. The Table view lists every filed value, including operating and net margins, total debt, and share count.
Visual explainers
The filing-backed explainer service is temporarily unavailable, so no partial or guessed chart is shown.
Moat Score history
Breaks in the line mark methodology or normalizer upgrades — readings across versions aren’t compared, so a level shift there isn’t a change in the business.
Tier changesSame-methodology and same-normalizer crossings of the Wide / Narrow / Shallow bars
- Normalizer upgraded unstamped (version unknown)tomoat-xbrl-normalizer@1.1.0 — readings across versions aren’t comparedJul 26, 2026
- Methodology upgraded moat-index@2.0.0tomoat-index@3.0.0 — readings across versions aren’t comparedJul 23, 2026
- Methodology upgraded moat-index@1.2.0tomoat-index@2.0.0 — readings across versions aren’t comparedJul 20, 2026
Scores are logged append-only and never overwritten — this record cannot be reconstructed retroactively, which is exactly why it’s worth keeping.
Insider activity
Form 4 reports mix P/S market or private transactions with compensation-plan mechanics. Activity casually described as “insider selling” can include compensation mechanics; awards, tax withholding, and option exercises are shown by their exact filed class here, never collapsed into “Bought” or “Sold.”
These are disclosed filing facts and arithmetic aggregates, not a signal or verdict.
This machine-readable surface covers SEC ownership filings from 2003; it does not represent earlier paper-era records.
Records still being gathered — partial as of retrieval Sep 1, 2026.
Trailing-12-month totals and the 90-day cluster result are withheld because this issuer walk is incomplete.
No reported Form 4 rows were captured for NAGE; the incomplete walk cannot establish zero activity, zero counts, or a negative cluster result.
A filing source-event date will appear when a Form 4 row is captured.
Retrieved .
Healthcare context
#99 of 710 scored Healthcare companies, ranked by Moat Score.
Nearest peers by Moat Score
- #97DCTH DELCATH SYSTEMS, INC.61.7 out of 100, Narrow moatNarrow moat
- #98NVAX NOVAVAX, INC.61.6 out of 100, Narrow moatNarrow moat
- #100CDRE CADRE HOLDINGS, INC.61.4 out of 100, Narrow moatNarrow moat
- #101BIOE BIO ESSENCE CORP.61.2 out of 100, Narrow moatNarrow moat
Compare NAGE with its nearest peers →All Healthcare companies on the Index →
Common questions about NAGE
- Does Niagen Bioscience, Inc. have an economic moat?
- Based on its FY2025 SEC filings, the Moat Index scores Niagen Bioscience, Inc. (NAGE) 61.6 out of 100 — a Narrow moat. The five questions behind that score begin at 20% each; if exactly one genuinely lacks data, the other four weights are renormalized and disclosed. revenue and EPS trend 85, pricing power 91, returns on capital 8, balance-sheet safety 100, capital allocation 24.
- How has NAGE's Moat Score changed over time?
- The record logs 15 readings since Jul 17, 2026; the latest reads 61.6 out of 100 (narrow moat). No tier changes on record yet. (Methodology or normalizer upgrades on Jul 20, 2026, Jul 23, 2026, Jul 26, 2026 re-based the score; readings across versions aren't compared.) The history is append-only — readings are only ever added, never rewritten.